IL99119A - Method to generate improved oligosaccharide binding vaccines - Google Patents

Method to generate improved oligosaccharide binding vaccines

Info

Publication number
IL99119A
IL99119A IL9911991A IL9911991A IL99119A IL 99119 A IL99119 A IL 99119A IL 9911991 A IL9911991 A IL 9911991A IL 9911991 A IL9911991 A IL 9911991A IL 99119 A IL99119 A IL 99119A
Authority
IL
Israel
Prior art keywords
oligosaccharide
oligosaccharides
type
pneumoniae
polysaccharide
Prior art date
Application number
IL9911991A
Other languages
English (en)
Hebrew (he)
Other versions
IL99119A0 (en
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL99119A0 publication Critical patent/IL99119A0/xx
Publication of IL99119A publication Critical patent/IL99119A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL9911991A 1990-09-28 1991-08-07 Method to generate improved oligosaccharide binding vaccines IL99119A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/590,649 US5153312A (en) 1990-09-28 1990-09-28 Oligosaccharide conjugate vaccines

Publications (2)

Publication Number Publication Date
IL99119A0 IL99119A0 (en) 1992-07-15
IL99119A true IL99119A (en) 1996-11-14

Family

ID=24363087

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9911991A IL99119A (en) 1990-09-28 1991-08-07 Method to generate improved oligosaccharide binding vaccines

Country Status (21)

Country Link
US (2) US5153312A (fr)
EP (1) EP0477508B1 (fr)
JP (1) JP3027452B2 (fr)
KR (1) KR100217317B1 (fr)
CN (1) CN1034054C (fr)
AT (1) ATE124868T1 (fr)
AU (1) AU634663B2 (fr)
CA (1) CA2052323C (fr)
CZ (1) CZ285650B6 (fr)
DE (1) DE69111168T2 (fr)
FI (1) FI104046B (fr)
HU (1) HU211210B (fr)
IE (1) IE71671B1 (fr)
IL (1) IL99119A (fr)
NO (1) NO300759B1 (fr)
NZ (1) NZ239878A (fr)
PL (1) PL169926B1 (fr)
PT (1) PT99067B (fr)
SK (1) SK280112B6 (fr)
TW (1) TW324664B (fr)
ZA (1) ZA917771B (fr)

Families Citing this family (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US7279162B1 (en) 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US5622649A (en) * 1991-06-27 1997-04-22 Emory University Multiple emulsions and methods of preparation
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
EP0911036A3 (fr) * 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Structure immunogene à double vecteur
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
EP0618813B1 (fr) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigene de la proteine m hybride et porteur destine au vaccin anti-streptococcique du groupe a
US6531156B1 (en) 1994-04-15 2003-03-11 Temple University Aqueous solven encapsulation method, apparatus and microcapsules
AU695769B2 (en) * 1994-07-01 1998-08-20 Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The Helicobacter proteins and vaccines
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
IL121585A0 (en) * 1995-06-07 1998-02-08 Alberta Res Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of preparing and using them
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
CN1146444C (zh) 1995-06-23 2004-04-21 史密斯克莱·比奇曼生物公司 含有吸附于磷酸铝上的多糖偶联抗原的疫苗组合物
US6872398B2 (en) * 1995-12-22 2005-03-29 The United States Of America As Represented By The Secretary Of The Army Conjugate vaccine against gram-negative bacterial infections
WO1997025429A1 (fr) 1996-01-04 1997-07-17 Rican Limited Bacterioferritine de helicobacter pilori
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
JP4162267B2 (ja) * 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5847110A (en) * 1997-08-15 1998-12-08 Biomedical Frontiers, Inc. Method of reducing a schiff base
DE69830326T2 (de) 1997-10-03 2006-02-02 Galenica Pharmaceuticals, Inc. Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
CA2320470A1 (fr) 1998-02-05 1999-08-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procede simplifie d'elimination de proteine libre en cours de preparation de conjugues de proteine-polysaccharide et vaccins utilisant un support a acces restreint
CA2320223A1 (fr) * 1998-02-12 1999-08-19 American Cyanamid Company Vaccins pneumococciques ou meningococciques formules avec l'interleukine-12
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1073667A2 (fr) 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Conjugues d'antigene et de polysaccharide
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
NZ509986A (en) * 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
WO2001078787A2 (fr) * 2000-04-18 2001-10-25 Endobiologics, Incorporated Vaccin conjugue anti-sepsie
US7749511B2 (en) 2000-04-18 2010-07-06 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
ATE357461T1 (de) * 2000-08-25 2007-04-15 Aventis Pasteur Innen-kern oligosaccharide epitopes aus lipopolysacchariden von haemophilus influenza als vakzinen in der prophylaktischen behandlung von haemophilus influenzae infektionen
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
OA12590A (en) 2001-01-23 2006-06-08 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2458854A1 (fr) * 2001-08-31 2003-03-06 Chiron Srl Vaccination contre helicobacter pylori avec une combinaison de proteinescaga, vaca et nap
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
CA2476626A1 (fr) * 2002-02-20 2003-08-28 Chiron Corporation Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
AU2003206532A1 (en) * 2002-02-22 2003-09-09 National Research Council Of Canada Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue
AU2002309259A1 (en) * 2002-05-09 2003-11-11 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
DE60328481D1 (de) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
DK2255826T3 (en) 2002-08-02 2016-06-20 Glaxosmithkline Biologicals Sa Neisserial vaccine compositions comprising a combination of antigens.
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipéptidos para protecção alargada contra linhagens meningocócicas hipervirulentas
EP1556477B1 (fr) 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Sechage
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) * 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
CA2520124A1 (fr) 2003-03-28 2004-10-14 Chiron Corporation Utilisation de composes de benzazole pour l' immunostimulation
EP2386313A1 (fr) 2003-05-07 2011-11-16 Sanofi Pasteur, Inc. Conjugués de polysaccharides-protéines dérivatisés méningococciques multivalents et vaccin
BRPI0410423A (pt) 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
US20070020293A1 (en) * 2003-06-23 2007-01-25 Michon Francis J Vaccines against group neisseria meningitidis and meningococcal combinations thereof
BRPI0411875A (pt) 2003-06-23 2006-08-08 Sanofi Pasteur Inc método de imunização contra os sorogrupos a e c de neisseria meningitidis
US8574596B2 (en) 2003-10-02 2013-11-05 Glaxosmithkline Biologicals, S.A. Pertussis antigens and use thereof in vaccination
CA2885040C (fr) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Vaccins liquides contre de multiples serogroupes meningococciques
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
EP1699810A4 (fr) 2003-12-17 2009-10-21 Elan Pharm Inc Conjugues porteurs de peptide immunogene a beta les techniques de production de ces conjugues
EP1701968B1 (fr) 2003-12-17 2015-06-03 Wyeth LLC Conjugues porteurs de peptides immunogenes et procedes de production associes
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
WO2005072778A2 (fr) * 2004-01-29 2005-08-11 Biosynexus, Inc. Utilisation de groupes fonctionnels amino-oxy dans la preparation de vaccins
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408978D0 (en) 2004-04-22 2004-05-26 Chiron Srl Meningococcal fermentation for preparing conjugate vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
EP2272531A3 (fr) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Intégration du vaccin conjugué de méningococcus
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
WO2006002422A2 (fr) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Composes utilises pour l'immunopotentialisation
CA2575548A1 (fr) 2004-07-29 2006-07-27 John L. Telford Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
KR20070101207A (ko) 2004-08-30 2007-10-16 사노피 파스퇴르 인크 다가 수막구균 유도체화된 다당류-단백질 접합체 및 백신
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
JP2008513541A (ja) 2004-09-21 2008-05-01 サノフィ パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) * 2005-04-08 2023-08-08 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
AU2011253684B8 (en) * 2005-04-08 2013-07-11 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP1931380A2 (fr) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Vaccination multiple comprenant des meningocoques du serogroupe c
US7700578B2 (en) * 2005-09-21 2010-04-20 The United States Of America As Represented By The Secretary Of The Navy Capsule composition for use as immunogen against Campylobacter jejuni
EP1933865B1 (fr) * 2005-09-21 2016-03-09 The United States of America as represented by the Secretary of the Navy Composition d'une capsule immunogénique utilisée comme composant d'un vaccin contre campylobacter jejuni
US9999591B2 (en) * 2005-09-21 2018-06-19 The United States Of America As Represented By The Secretary Of The Navy Immunogenic composition against Campylobacter jejuni
GB0522303D0 (en) 2005-11-01 2005-12-07 Chiron Srl Culture method
WO2007081447A2 (fr) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Antigènes de norovirus et de sapovirus
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
MY160199A (en) 2005-12-22 2017-02-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP4822854B2 (ja) * 2006-01-18 2011-11-24 株式会社有沢製作所 フレキシブルプリント配線板用ポリアミドイミド樹脂、並びに該樹脂を用いた金属張り積層板、カバーレイ、フレキシブルプリント配線板、及び樹脂組成物
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
EP2357184B1 (fr) 2006-03-23 2015-02-25 Novartis AG Composés d'imidazoquinoxaline en tant qu'immunomodulateurs
EP2007765B1 (fr) 2006-03-23 2012-06-27 Novartis AG Composes de potentialisation immunitaire
EP2010530A2 (fr) * 2006-03-23 2009-01-07 Novartis AG Procedes de preparation de composes contenant de l'imidazole
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008020335A2 (fr) 2006-06-09 2008-02-21 Novartis Ag Compositions immunogènes pour streptococcus agalactiae
CN110064053A (zh) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
MX2009001412A (es) 2006-08-07 2009-04-24 Harvard College Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
DK2457920T3 (en) * 2007-01-18 2018-01-22 Genzyme Corp Oligosaccharides comprising an amino oxy group and conjugates thereof
CN103933564A (zh) 2007-05-02 2014-07-23 葛兰素史密丝克莱恩生物有限公司 疫苗
NZ581367A (en) 2007-06-04 2012-05-25 Novartis Ag Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
DK2167121T3 (en) 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
WO2009034473A2 (fr) 2007-09-12 2009-03-19 Novartis Ag Antigènes mutants gas57 et anticorps gas57
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (zh) 2007-12-21 2014-10-08 诺华股份有限公司 链球菌溶血素o的突变形式
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
WO2010083477A2 (fr) 2009-01-16 2010-07-22 University Of Maryland, Baltimore Vaccin à large spectre contre les salmonelles non typhoïdiques
US20120135037A1 (en) 2009-06-01 2012-05-31 Mizel Steven B Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
WO2011017101A2 (fr) 2009-07-27 2011-02-10 Fina Biosolutions, Llc Procédé de production de vaccins à protéine-carbohydrate à niveau réduit de carbohydrate libre
RU2603267C2 (ru) 2009-09-30 2016-11-27 Новартис Аг Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2493498B1 (fr) 2009-10-30 2017-03-22 GlaxoSmithKline Biologicals SA Purification de saccharides capsulaires de staphylococcus aureus de type 5 et de type 8
SG10201506160VA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
US20130004530A1 (en) 2010-03-10 2013-01-03 Jan Poolman Vaccine composition
EP2547357A1 (fr) 2010-03-18 2013-01-23 Novartis AG Vaccins adjuvantés contre le méningocoque de sérogroupe b
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
WO2011133227A2 (fr) 2010-04-23 2011-10-27 Ancora Pharmaceuticals Inc. Oligosaccharides synthétiques pour un vaccin contre staphylococcus
WO2011137181A1 (fr) 2010-04-27 2011-11-03 Ancora Pharmaceuticals Inc. Oligosaccharides synthétiques pour vaccins contre moraxella
WO2011149778A1 (fr) 2010-05-26 2011-12-01 Ancora Pharmaceuticals Inc. Oligosaccharides synthétiques pour un vaccin contre neisseria meningitidis
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US20130171185A1 (en) 2010-07-06 2013-07-04 Ethan Settembre Norovirus derived immunogenic compositions and methods
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
CN102068690A (zh) * 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
EP2680885B8 (fr) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Vaccins combinés comprenant des doses inférieures d'antigène et/ou d'adjuvant
WO2012130764A1 (fr) 2011-03-29 2012-10-04 Bayer Materialscience Ag Utilisation d'une préparation aqueuse pour revêtement de surfaces en bois destinée à créer une sensation de toucher naturel
ES2641090T3 (es) 2011-03-29 2017-11-07 Covestro Deutschland Ag Uso de una preparación acuosa para el revestimiento de superficies de madera para lograr un efecto de tacto natural
GB201106225D0 (en) 2011-04-13 2011-05-25 Glaxosmithkline Biolog Sa Fermentation process
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
ES2687129T3 (es) 2011-07-25 2018-10-23 Glaxosmithkline Biologicals Sa Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
EP2755683B1 (fr) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Procédés de production de glycoconjugués de saccharide-protéine
CN104080479B (zh) 2011-11-07 2019-11-05 葛兰素史密丝克莱恩生物有限公司 包括spr0096和spr2021抗原的运载体分子
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2822584A1 (fr) 2012-03-08 2015-01-14 Novartis AG Vaccins combinés comprenant des agonistes du tlr4
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
US20160101187A1 (en) 2012-10-02 2016-04-14 Novartis Ag Nonlinear saccharide conjugates
KR20150073160A (ko) 2012-10-03 2015-06-30 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
MX2015004652A (es) 2012-10-12 2015-08-05 Glaxosmithkline Biolog Sa Antigenos de pertusis acelulares no entrelazados para uso en vacunas de combinacion.
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP2743695A1 (fr) 2012-12-12 2014-06-18 Nanogap Sub NM Powder, S.A. Procédés et réactifs pour la détection de biomolécules au moyen de luminescence
JP2016502994A (ja) 2012-12-18 2016-02-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ジフテリア及び／又は破傷風から防御するためのコンジュゲート
BR122020000550B1 (pt) * 2012-12-20 2021-12-07 Pfizer Inc Composição imunogênica que compreende pn-sorotipo 12f conjugado com uma proteína carreadora e seu uso
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US8916173B2 (en) 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
BR112016000210A2 (pt) * 2013-07-07 2017-08-22 Max Planck Gesellschaft Vacinas sintéticas contra streptococcus pneumoniae tipo 1
EA201690205A1 (ru) 2013-07-11 2016-12-30 Новартис Аг Сайт-специфические химико-ферментативные модификации белков
WO2015033251A2 (fr) 2013-09-08 2015-03-12 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procédés associés
HRP20231504T1 (hr) * 2014-01-21 2024-03-01 Pfizer Inc. Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
EP3193918A4 (fr) 2014-09-18 2018-06-20 University of Maryland, Baltimore Vaccin conjugué à large spectre permettant de prévenir des infections par klebsiella pneumoniae et pseudomonas aeruginosa
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
JP2017537145A (ja) 2014-11-05 2017-12-14 ザ ユナイテッド ステイツ オブ アメリカ アズ レプレゼンティッド バイ ザ セクレタリー オブ ザ ネイビーＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ Ｏｆ Ａｍｅｒｉｃａ Ａｓ Ｒｅｐｒｅｓｅｎｔｅｄ Ｂｙ Ｔｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｔｈｅ Ｎａｖｙ カンピロバクター・ジェジュニに対する合成抗原コンストラクト
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (fr) * 2015-11-20 2023-10-10 Pfizer Inc. Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
WO2018074296A1 (fr) 2016-10-20 2018-04-26 一般財団法人化学及血清療法研究所 PROCÉDÉ DE PRODUCTION D'UN VACCIN CONJUGUÉ CONTRE Hib À L'AIDE D'UNE PRP DE FAIBLE POIDS MOLÉCULAIRE
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
KR20190108583A (ko) 2017-01-31 2019-09-24 머크 샤프 앤드 돔 코포레이션 다당류-단백질 접합체 제조 방법
KR20220011796A (ko) 2017-01-31 2022-01-28 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
WO2019203599A1 (fr) * 2018-04-18 2019-10-24 에스케이바이오사이언스 주식회사 Polysaccharides capsulaires de streptococcus pneumoniae et conjugués immunogènes de ceux-ci
US12018134B2 (en) 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
WO2020043874A1 (fr) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3757217A1 (fr) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Procédés de purification de protéines
EP3777884A1 (fr) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Composition immunogène
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer Composições para neisseria meningitidis e métodos das mesmas
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
EP3900739A1 (fr) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Conjugués saccharides synthétiques de streptococcus pneumoniae à une protéine de membrane conservée
EP3919076A1 (fr) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccins synthétiques d'oligosaccharide contre le streptococcus pneumoniae avec des formulations d'adjuvant de microparticules
WO2021250628A1 (fr) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Immunisation bactérienne à l'aide d'un vaccin à nanoparticules
WO2021259743A2 (fr) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccin
CA3201450A1 (fr) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Transporteurs de proteine bacterienne et procedes de conjugaison
WO2023111826A1 (fr) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Immunisation bactérienne utilisant des constructions de nanoparticules en épingle à cheveux qbêta
WO2023200704A1 (fr) 2022-04-11 2023-10-19 Sanofi Pasteur Inc. Conjugaison protéine-saccharide avec du cyanoborohydrure de sodium
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4314988A (en) * 1979-10-31 1982-02-09 Baker Instruments Corp. Folic acid derivatives and process for preparation
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines

Also Published As

Publication number Publication date
AU634663B2 (en) 1993-02-25
FI914564A0 (fi) 1991-09-27
IE913399A1 (en) 1992-04-08
CA2052323A1 (fr) 1992-03-29
HU913103D0 (en) 1992-01-28
US5153312A (en) 1992-10-06
CN1034054C (zh) 1997-02-19
NO300759B1 (no) 1997-07-21
TW324664B (en) 1998-01-11
CS296991A3 (en) 1992-04-15
ZA917771B (en) 1992-06-24
AU8483391A (en) 1992-04-02
NZ239878A (en) 1993-09-27
DE69111168D1 (de) 1995-08-17
SK280112B6 (sk) 1999-08-06
PL169926B1 (pl) 1996-09-30
FI104046B1 (fi) 1999-11-15
FI914564A (fi) 1992-03-29
FI104046B (fi) 1999-11-15
PL291855A1 (en) 1992-10-05
JP3027452B2 (ja) 2000-04-04
EP0477508A1 (fr) 1992-04-01
EP0477508B1 (fr) 1995-07-12
PT99067B (pt) 1999-02-26
CA2052323C (fr) 2001-04-17
US5306492A (en) 1994-04-26
KR100217317B1 (ko) 1999-10-01
HU211210B (en) 1995-11-28
HUT58529A (en) 1992-03-30
CZ285650B6 (cs) 1999-10-13
DE69111168T2 (de) 1996-04-04
CN1060294A (zh) 1992-04-15
IL99119A0 (en) 1992-07-15
NO913812D0 (no) 1991-09-27
IE71671B1 (en) 1997-02-26
JPH06340550A (ja) 1994-12-13
PT99067A (pt) 1992-08-31
ATE124868T1 (de) 1995-07-15
KR920006366A (ko) 1992-04-27
NO913812L (no) 1992-03-30

Similar Documents

Publication Publication Date Title
EP0477508B1 (fr) Vaccins améliorés à base de conjugués d'oligosaccharides
Chu et al. Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates
US4902506A (en) Immunogenic conjugates
US5360897A (en) Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
Paoletti et al. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Chu et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid
Beuvery et al. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates
US4673574A (en) Immunogenic conjugates
US4761283A (en) Immunogenic conjugates
US5097020A (en) Immunogenic conjugates
US4762713A (en) Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
CA2145397C (fr) Vaccins conjugues polysaccharides-proteines contre des streptocoques du groupe b de types ii et v
Cryz Jr et al. Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines
Robbins et al. Prevention of invasive bacterial diseases by immunization with polysaccharide-protein conjugates
Peeters et al. Preparation of polysaccharide-conjugate vaccines
Porro et al. A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria
Svenson et al. Artificial salmonella vaccines
Robbins et al. Bacterial antigens cross-reactive with the capsular polysaccharides of Haemophilus influenzae type b, Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and III
Liao et al. Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi
Robbins Prevention of Invasive Bacterial Diseases by Immunization with Polysaccharide-Protein Conjugates JB Robbins, R. Schneerson, SC Szu, A. Fattom, Y. Yang, T. Lagergard, C. Chu, and US Sørensen Laboratory of Development and Molecular Immunity, National Institute of Child
Pozsgay Bacterial polysaccharide-protein conjugate
Makela et al. Vaccines Against Bacterial Infections of Children

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees